Eleven Biotherapeutics

Press Releases
 
Press Releases
Date Title and Summary View
August 16, 2016 Eleven entitled to $30 million payment CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the effectiveness of the exclusive licensing deal ...
August 12, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the second quarter ended June 30, 2016 and provided a review of recent business highlights...
July 7, 2016 Eleven entitled to receive $22.5 million milestone payment for IND effectiveness CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced...
June 13, 2016 License to Roche Covers IL-6 Antagonist Antibody Technology, Including EBI-031 IND Submission for EBI-031 Announced Today CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a biopharmaceutical company discovering and developing protein th...
June 13, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (F...
May 5, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the first quarter ended March 31, 2016 and provided a review of recent business highlights...
April 29, 2016 Preclinical Data on EBI-031 in Diabetic Macular Edema and Clinical Data on Isunakinra (EBI-005) in Dry Eye Disease and Allergic Conjunctivitis to be Presented CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and...
March 24, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a preclinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2015 and pr...
January 26, 2016 Cambridge, MA and Copenhagen, Denmark - January 26, 2016 - Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) and Albumedix (DK A/S) today announced that Eleven and Albumedix have entered into an agreement that will see Albumedix acquire Eleven's proprietary Supermin® albumin variant assets. Albumedix is a world leader in albumin engineer...
January 15, 2016 -Isunakinra Misses Primary Endpoint of Ocular Itching- -Company Plans to Advance Development of EBI-031 for Diabetic Macular Edema and Uveitis with an IND Submission Planned for the First Half of 2016- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. ...
FirstPrevious
2
... NextLast
Add to Briefcase = add release to Briefcase
NASDAQ: EBIO
Price:
2.25
Change:
0.00
Day High:
N/A
Day Low:
N/A
Volume:
N/A
4:00 PM ET on March 28, 2017
Delayed at least 20 minutes.